4//SEC Filing
Mulligan Margaret Jean 4
Accession 0001477126-10-000005
CIK 0000885590other
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 5:46 PM ET
Size
9.8 KB
Accession
0001477126-10-000005
Insider Transaction Report
Form 4
Mulligan Margaret Jean
EVP, CFO
Transactions
- Exercise/Conversion
Common Shares, no par value
2010-11-08+102,658→ 130,658 total - Tax Payment
Common Shares, no par value
2010-11-08$26.12/sh−47,644$1,244,461→ 83,014 total - Exercise/Conversion
Restricted Share Units
2010-11-08−51,329→ 0 totalFrom: 2010-11-08Exp: 2014-08-05→ Common Shares, no par value (51,329 underlying)
Footnotes (3)
- [F1]Each Restricted Share Unit ("RSU") represents a contingent right to receive one common share, no par value, of Valeant Pharmaceuticals International, Inc. and is subject to performance based vesting criteria, providing for vesting ranging from zero (0) to two hundred percent (200%).
- [F2]Represents performance based RSUs that accelerated at 200% in connection with the merger between the issuer (formerly known as Biovail Corporation) and Valeant Pharmaceuticals International and vested following the completion of the issuer's blackout period restrictions on November 8, 2010.
- [F3]Common shares withheld from the issuance of common shares to the Reporting Person to satisfy the tax withholding obligations due upon vesting of RSUs.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeother
Related Parties
1- filerCIK 0001477287
Filing Metadata
- Form type
- 4
- Filed
- Nov 9, 7:00 PM ET
- Accepted
- Nov 10, 5:46 PM ET
- Size
- 9.8 KB